Clinical effect of valsartan combined with folic acid in the treatment of elderly hypertensive nephropathy and the changes of related inflammatory factors
缬沙坦联合叶酸治疗老年高血压肾病的临床效果及相关炎性因子改变观察分析

摘要

目的 分析老年高血压肾病患者运用缬沙坦联合叶酸治疗的临床有效性及相关炎性因子改变。方法本文病例筛选2020年2月—2022年2月期间我院全科门诊诊治的老年高血压肾病患者48例，根据随机数字表分组方式将所纳入的患者分成对照与观察两组各24例，对照组患者治疗运用单独缬沙坦；观察组患者采取缬沙坦与叶酸联合方案治疗，将最终两组治疗方案获得的临床效果进行对比。结果 治疗后两组各项指标结果比较显示，观察组患者的血压水平和炎性因子指标同对照组相比均得到显著改善，且观察组患者治疗后的肾功能损伤程度与对照组相比无明显进展，组间指标对比差异统计学意义存在（P＜0.05）；最终观察组患者取得的治疗总有效率也显著高于对照组，两组指标差值有统计学意义（P＜0.05）；观察组患者的生活质量与对照组相比显著提高，组间数据结果比较差值存在统计学意义（P＜0.05）。结论 运用缬沙坦联合叶酸治疗老年高血压肾病，能够进一步提升临床治疗效果，确保患者血压保持的平稳状态，减轻患者肾功能损伤程度，降低疾病对患者健康及生活造成的影响。

Abstract

Objective: To analyze the clinical efficacy of valsartan combined with folic acid in elderly patients with hypertensive nephropathy and the changes of related inflammatory factors.
Methods:48 elderly patients with hypertensive nephropathy diagnosed and treated in the general outpatient department of our hospital from February 2020 to February 2022 were selected. According to the grouping method of random number table, the included patients were divided into control group and observation group, with 24 cases in each group. The patients in the control group were treated with valsartan alone; The patients in the observation group were treated with the combination of valsartan and folic acid, and the clinical effects of the two groups were compared.
Results:after treatment, the results of the two groups showed that the blood pressure level and inflammatory factors in the observation group were significantly improved compared with those in the control group, and there was no significant progress in the degree of renal function injury in the observation group compared with those in the control group. There was a statistically significant difference in the indexes between the two groups (P<0.05); The total effective rate of the observation group was also significantly higher than that of the control group, and the difference between the two groups was statistically significant (P<0.05); Compared with the control group, the quality of life of the patients in the observation group was significantly improved, and the difference of data results between the groups was statistically significant (P<0.05).
Conclusion  : Valsartan combined with folic acid in the treatment of elderly hypertensive nephropathy can further improve the clinical treatment effect, ensure that the blood pressure of patients remains stable, reduce the degree of renal function damage, and reduce the impact of the disease on the health and life of patients.